EUVIMEDEUVIMED entdecken
Open Access

Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy

Qi Gao iD, Ying Liu, Umut Aypar, Jeeyeon Baik, Dory Londono, Xiaotian Sun, Jingping Zhang, Yanming Zhang, Mikhail Roshal

Cytometry Part B: Clinical Cytometry · 2023

DOI: 10.1002/cyto.b.22120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2023. Verfasst von Qi Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Measurement of minimal/measurable residual disease (MRD) in B‐lymphoblastic leukemia/lymphoma (B‐ALL) has become a routine clinical evaluation tool and remains the strongest predictor of treatment outcome. In recent years, new targeted anti‐CD19 and anti‐CD22 antibody‐based and cellular therapies have revolutionized the treatment of the high‐risk B‐ALL. The new treatments raise challenges for diagnostic flow cytometry, which relies on the presence of specific surface antigens to identify the population of interest. So far, reported flow cytometry‐based assays are developed to either achieve a deeper MRD level or to accommodate the loss of surface antigens post‐target therapies, but not both.

Methods

We developed a single tube flow cytometry assay (14‐color‐16‐parameters). The method was validated using 94 clinical samples as well as spike‐in and replicate experiments.

Results

The assay was well suited for monitoring response to targeted therapies and reached a sensitivity below 10 −5 with acceptable precision (coefficient of variation < 20%), accuracy, and interobserver variability ( κ = 1).

Conclusions

The assay allows for sensitive disease detection of B‐ALL MRD independent of CD19 and CD22 expression and allows uniform analysis of samples regardless of anti‐CD19 and CD22 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaLymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansFlow CytometryAntigens, SurfaceAntigens, CD19Neoplasm, Residual

Stichwörter der Autor:innen

B-ALLflow cytometrymeasurable residual diseasetarget therapy

Substanzen

Antigens, SurfaceAntigens, CD19

Autor:innen und Institutionen

  • Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Qi Gao

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Gao, Q., Liu, Y., Aypar, U., Baik, J., Londono, D., Sun, X., Zhang, J., Zhang, Y., & Roshal, M. (2023). Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22120

Vancouver

Gao Q, Liu Y, Aypar U, Baik J, Londono D, Sun X, et al. Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy. Cytometry Part B: Clinical Cytometry. 2023. doi:10.1002/cyto.b.22120

BibTeX
@article{Gao2023,
  author = {Gao, Qi and Liu, Ying and Aypar, Umut and Baik, Jeeyeon and Londono, Dory and Sun, Xiaotian and Zhang, Jingping and Zhang, Yanming and Roshal, Mikhail},
  title = {Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2023},
  doi = {10.1002/cyto.b.22120}
}
Kostenlos starten →